# Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

> **NCT00293475** · PHASE1,PHASE2 · UNKNOWN · sponsor: **OHSU Knight Cancer Institute** · enrollment: 81 (estimated)

## Conditions studied

- Central Nervous System Lymphoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Mannitol
- **DRUG:** Methotrexate
- **OTHER:** Quality-of-Life Assessment
- **BIOLOGICAL:** Rituximab
- **DRUG:** Sodium Thiosulfate

## Key facts

- **NCT ID:** NCT00293475
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-10-14
- **Primary completion:** 2022-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2021-09-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293475, "Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00293475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*